Filing Analysis
InspireMD, Inc. issued an 8-K to furnish its financial and operating results for the three and six months ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: August 17, 2026
- Reporting period: Three and six months ended June 30, 2026
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
InspireMD, Inc. announced the elimination of the Chief Commercial Officer position held by Shane Gleason. His employment with the company is scheduled to terminate on July 31, 2026.
🚩 Red Flags
- Elimination of a C-suite position (Chief Commercial Officer) may indicate restructuring or cost-cutting measures.
📋 Key Facts
- Effective date of departure: July 31, 2026
- Officer departing: Shane Gleason
- Title: Chief Commercial Officer
- Reason for departure: Position eliminated
InspireMD, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum $1.00 bid price requirement after failing to maintain that price for 30 consecutive business days ending July 16, 2026.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Potential for a reverse stock split to regain compliance
- Risk of delisting if compliance is not met by January 2027 or subsequent extension periods
📋 Key Facts
- Received Nasdaq Notice on July 17, 2026.
- Non-compliance period: June 3, 2026, through July 16, 2026 (30 consecutive business days).
- Requirement: Minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
- Compliance period granted until January 13, 2027.
- To regain compliance, stock must close at $1.00+ for at least 10 consecutive business days during the period.
- Company is considering a reverse stock split as a potential remedy to meet requirements.
InspireMD, Inc. announced the resignation of Raymond W. Cohen from the Board of Directors and his roles on the Audit and Compensation Committees. The resignation is effective July 1, 2026, and is reportedly for personal reasons with no disagreement with management.
🚩 Red Flags
- Loss of board member serving on key oversight committees (Audit and Compensation).
📋 Key Facts
- Raymond W. Cohen resigned as a Class III member of the Board of Directors, effective July 1, 2026.
- Mr. Cohen also vacated his positions on the Audit Committee and the Compensation Committee.
- The company stated the resignation is for personal considerations and not due to any disagreement with the Company, its Board, or management.
- The Nominating and Corporate Governance Committee is tasked with finding a replacement.
InspireMD, Inc. issued a press release on June 11, 2026, announcing the 30-day results from the CGUARDIANS II clinical trial regarding the CGuard Prime 80 cm implant used in TCAR procedures.
📋 Key Facts
- The filing reports the release of 30-day clinical trial results for the CGUARDIANS II study.
- The study focuses on the CGuard Prime 80 cm Implant for use in Transcarotid Artery Revascularization (TCAR) procedures.
- The information was furnished under Item 7.01 (Regulation FD Disclosure).
InspireMD held its 2026 Annual Meeting of stockholders on June 3, 2026, where shareholders approved an increase in the authorized number of common stock shares. The company also re-elected three directors and ratified its independent auditors.
🚩 Red Flags
- Significant increase in authorized shares (66.7% increase) often precedes dilutive capital raises or equity-based financing in micro-cap companies.
📋 Key Facts
- Authorized common stock increased from 150,000,000 shares to 250,000,000 shares.
- The amendment became effective on June 3, 2026, following filing with the Secretary of State of Delaware.
- Directors Marvin Slosman, Raymond Cohen, and Dan Dearen were re-elected as Class 3 directors for three-year terms.
- Kesselman & Kesselman (PwC International Limited) was ratified as the independent registered public accounting firm for fiscal year 2026.
- Quorum was established with 34,631,348 shares represented (73.85% of the 46,892,979 outstanding shares).
On May 20, 2026, Paul Stuka, the Chair of the Board of Directors of InspireMD, Inc., notified the company of his decision to retire and not seek reelection at the 2027 Annual Meeting of Stockholders. He intends to continue serving in his current roles until his term expires at the 2027 meeting.
📋 Key Facts
- Mr. Paul Stuka notified the company of his decision to retire and not seek reelection on May 20, 2026.
- Mr. Stuka currently serves as the Chair of the Board, Chair of the Compensation Committee, and as a member of both the Audit and Nominating and Corporate Governance Committees.
- His retirement will take effect at the 2027 Annual Meeting of Stockholders, allowing for a long transition period.
- The company stated that his decision did not result from any disagreement with the company on any matter relating to operations, policies, or practices.
InspireMD, Inc. announced its financial and operating results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- Reported financial results for the first quarter ended March 31, 2026
- Press release dated May 4, 2026, was furnished as Exhibit 99.1
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
InspireMD announced a voluntary recall of its CGuard Prime 135 cm delivery system in the U.S. due to performance issues during its controlled launch. Offsetting this negative development, the company received FDA IDE approval to initiate the CGUARDIANS III pivotal study for its SwitchGuard neuro protection system.
🚩 Red Flags
- Product recall during the critical 'controlled launch' phase in the U.S. market.
- Failure of the delivery system to meet performance expectations, which may impact clinician trust and adoption.
📋 Key Facts
- Voluntary recall initiated on May 1, 2026, for the CGuard Prime 135 cm carotid stent delivery system.
- The recall was triggered because technical success during carotid artery stenting (CAS) procedures did not meet performance expectations.
- The recall is limited to the delivery system and does not affect the CGuard stent implant itself.
- FDA approved the Investigational Device Exemption (IDE) for the CGUARDIANS III pivotal study.
- The new study will evaluate the SwitchGuard neuro protection system (NPS) with the CGuard Prime 80 cm stent platform in TCAR procedures.
InspireMD, Inc. established a new $75 million 'at-the-market' (ATM) equity distribution agreement with BTIG, LLC and terminated its previous ATM agreement with Piper Sandler & Co.
🚩 Red Flags
- Potential for significant shareholder dilution through the $75 million ATM facility.
- Continuous reliance on equity issuance to fund operations (R&D and marketing).
📋 Key Facts
- Entered into an Equity Distribution Agreement with BTIG, LLC on April 3, 2026.
- The agreement allows for the sale of up to $75,000,000 in common stock.
- BTIG is entitled to a commission of up to 3.0% of gross proceeds.
- Terminated a prior equity distribution agreement with Piper Sandler & Co. effective April 3, 2026.
- The company sold 1,361,519 shares under the previous Piper Sandler agreement prior to termination.
- Proceeds are intended for R&D, sales, marketing, and working capital.
InspireMD, Inc. reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. The company also released an updated investor presentation to provide strategic highlights to the market.
📋 Key Facts
- Financial results for the fiscal year ended December 31, 2025, were announced on March 18, 2026.
- An updated investor presentation was made available on the company's website and filed as an exhibit.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
InspireMD, Inc. has dismissed its Chief Operating Officer, Andrea Tommasoli, effective February 27, 2026. Mr. Tommasoli will be released from his duties on April 1, 2026, but will remain on the payroll through a six-month notice period ending September 1, 2026, in accordance with French labor law.
🚩 Red Flags
- The termination is characterized as a 'dismissal' rather than a resignation, which may indicate performance issues or a strategic disagreement.
📋 Key Facts
- Notice of dismissal provided to COO Andrea Tommasoli on February 27, 2026.
- Employment is governed by French law under a contract dated November 2, 2020.
- Mr. Tommasoli will be released from duties on April 1, 2026, but his last day of employment is expected to be September 1, 2026.
- Severance pay is estimated at approximately €61,000 gross plus accrued leave.
- Health and provident benefits will continue for a maximum of 12 months post-termination.
Kathryn Arnold has resigned from the Board of Directors and various committees, effective December 31, 2025. The resignation is reportedly not due to any disagreements with the company's operations or management.
🚩 Red Flags
- None identified; resignation is characterized as non-dispute related and includes standard recognition/severance terms.
📋 Key Facts
- Resignation date: Effective December 31, 2025.
- Departure roles: Class III member of the Board, Compensation Committee, Nominating and Corporate Governance Committee, and R&D Committee.
- Compensation package: Acceleration of unvested equity awards and a two-year extension on stock option expiration dates.
- Severance/Recognition: Payment of three additional quarters of committee fees and an aggregate grant of common stock and options valued at approximately $140,000 (75% stock / 25% options).
- Stated reason for departure: No disagreement with the Company, Board, or management.
InspireMD, Inc. filed an 8-K to announce its financial and operating results for the three and nine months ended September 30, 2025. The filing also includes an updated investor presentation.
📋 Key Facts
- Announced financial and operating results for the periods ending September 30, 2025 (three and nine months).
- Released an updated investor presentation on November 4, 2025.
- Filed under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
InspireMD, Inc. announced the resignation of Thomas J. Kester from the Board and his roles as Audit Committee Chairman and Compensation Committee member, effective September 16, 2025. He is being replaced by Danny Lee Dearen Jr., an experienced medical device executive and SEC-qualified audit committee financial expert.
🚩 Red Flags
- None identified; the resignation is stated to be non-dispute related.
📋 Key Facts
- Thomas J. Kester resigned from the Board, Audit Committee (Chairman), and Compensation Committee effective September 16, 2025.
- Kester's resignation was not due to any disagreement with the Company or its management.
- Danny Lee Dearen Jr. appointed as Class III director, Audit Committee Chairman, and Compensation Committee member effective September 16, 2025.
- Dearen received an equity grant (75% Restricted Stock / 25% Options) valued at approximately $180,000, vesting on a one-year anniversary.
- Kester was granted accelerated unvested equity and extended option expiration dates totaling approximately $120,000 in recognition of his service.
This is an amendment to a previous 8-K filing regarding the appointment of Raymond W. Cohen to the Board of Directors. The amendment specifically announces his assignment to the Audit and Compensation Committees.
📋 Key Facts
- Raymond W. Cohen was originally appointed as a Class 3 director on July 31, 2025.
- On September 7, 2025, the Board officially appointed Mr. Cohen to the Audit Committee and the Compensation Committee.
- Mr. Cohen's term is set to expire at the Company’s 2026 annual meeting of stockholders.
InspireMD, Inc. filed an 8-K to announce its financial and operating results for the three and six months ended June 30, 2025, and released an updated investor presentation.
📋 Key Facts
- Reported financial and operating results for the periods ending June 30, 2025 (three and six months).
- Released an updated investor presentation on August 5, 2025.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation).
InspireMD, Inc. announced a significant $40.1 million private placement of common stock and pre-funded warrants, alongside the completion of a $17.9 million warrant exercise. The company also expanded its Board with the appointment of an experienced industry veteran while announcing upcoming voluntary resignations of two directors.
🚩 Red Flags
- Significant potential dilution: The offering includes pre-funded warrants for up to 9,764,804 shares and follows a prior $17.9M warrant exercise.
- Registration Rights Agreement obligations: Company must file registration statements within tight timelines (20-90 days) or face liquidated damages.
📋 Key Facts
- Entered into a securities purchase agreement for 6,791,380 shares and pre-funded warrants at $2.42/$2.4199 per share.
- Aggregate gross proceeds from the new private placement are approximately $40.1 million.
- Completed exercise of 12.9 million Series I warrants, generating ~$17.9 million in gross proceeds.
- Appointed Raymond W. Cohen to the Board; Mr. Cohen previously served as CEO of Axonics, Inc. (acquired by Boston Scientific).
- Two directors, Kathryn Arnold and Thomas Kester, announced they will not seek reelection and plan to resign on Dec 31, 2025.
- The company is obligated to file a resale registration statement within 20 days of the signing date.
InspireMD, Inc. announced the U.S. commercial launch of its CGuard® Prime Carotid Stent System for stroke prevention via a press release furnished under Item 7.01.
📋 Key Facts
- Company issued a press release on July 9, 2025, regarding the U.S. commercial launch of CGuard® Prime Carotid Stent System.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information provided in Exhibit 99.1 is furnished but not 'filed' for purposes of Section 18 liability.
InspireMD, Inc. announced that the U.S. FDA has granted Premarket Approval (PMA) for its CGuard Prime Carotid Stent System on June 23, 2025.
📋 Key Facts
- FDA granted PMA approval for the CGuard Prime Carotid Stent System on June 23, 2025.
- The company issued a press release and an updated investor presentation regarding the approval on June 24, 2025.
- The product is intended for the prevention of stroke via carotid stent application.
InspireMD, Inc. announced that its CGuard® Prime Embolic Prevention System (EPS) has received CE Mark approval under the European Medical Device Regulation (MDR). This regulatory milestone is intended for stroke prevention.
📋 Key Facts
- Received CE Mark approval under European MDR on June 13, 2025.
- The approval applies to the CGuard® Prime Embolic Prevention System (EPS).
- The announcement was made via a press release furnished as Exhibit 99.1.
InspireMD, Inc. announced the appointment of Michael Lawless as Chief Financial Officer, effective by June 30, 2025, succeeding Craig Shore. The filing details a comprehensive employment agreement for Mr. Lawless, including base salary, performance bonuses, and significant change-in-control provisions.
🚩 Red Flags
- Executive turnover (CFO departure) can sometimes signal internal friction or transition periods, though not explicitly stated as such here.
- Significant change-in-control/severance obligations for the new CFO.
📋 Key Facts
- Michael Lawless appointed as CFO; will succeed Craig Shore by June 30, 2025.
- Mr. Lawless's compensation includes a $375,000 annual base salary and an annual performance bonus of up to 50% of base salary.
- Employment term is three years with automatic one-year renewals.
- Inducement grant: 212,000 stock options and 465,000 shares of restricted stock vesting over three years.
- Change in control provisions include 12 months of severance pay and 100% acceleration of unvested equity.
InspireMD, Inc. held its 2025 annual meeting of stockholders on June 3, 2025. The company successfully re-elected two directors and ratified its independent auditor for the fiscal year.
📋 Key Facts
- Annual Meeting held on June 3, 2025.
- Quorum was established with 20,478,807 shares (66.84% of outstanding shares) present in person or by proxy.
- Michael Berman and Scott R. Ward were re-elected to the Board of Directors for three-year terms.
- Kesselman & Kesselman was ratified as the independent registered public accounting firm for fiscal year 2025.
InspireMD, Inc. filed an 8-K to furnish its quarterly financial and operating results for the first quarter ended March 31, 2025 via a press release.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: First quarter ended March 31, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 liability.
InspireMD, Inc. filed an 8-K to announce its financial and operating results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 12, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing serves to incorporate a press release (Exhibit 99.1) regarding financial results.
InspireMD, Inc. announced the upcoming retirement of CFO Craig Shore and has amended his employment agreement to include significant severance terms in the event of termination without cause.
🚩 Red Flags
- Significant severance liability: The 'Shore Amendment' creates a substantial potential cash outflow if the company terminates him without cause, specifically including 200% of base salary plus 24 months of benefits/car costs.
- Executive turnover in a micro-cap environment can signal internal instability or shifts in financial strategy.
📋 Key Facts
- CFO Craig Shore will retire effective upon the appointment of a successor; he remains in role until then to assist with transition.
- The company is currently searching for a new CFO.
- A ninth amendment to Mr. Shore's employment agreement was entered into on December 10, 2024.
- Severance terms for termination without cause include: (A) 200% of annual base salary, (B) two times the annual cost of an automobile, and (C) compensatory benefits equivalent to what he would have received over the next 24 months.
InspireMD, Inc. announced the enrollment of the first patient in its CGUARDIANS II pivotal clinical study. This trial evaluates the CGuard Prime Carotid Stent System for use in Transcarotid Artery Revascularization (TCAR) procedures.
📋 Key Facts
- First patient enrolled in the CGUARDIANS II pivotal study as of December 9, 2024.
- The study evaluates the CGuard Prime Carotid Stent System.
- The clinical application is Transcarotid Artery Revascularization (TCAR) procedures.
InspireMD, Inc. has appointed Scott R. Ward to its Board of Directors as a Class II member. The appointment includes equity compensation in the form of stock options and restricted stock.
📋 Key Facts
- Scott R. Ward appointed to the Board effective November 25, 2024.
- Granted 16,647 stock options with a 10-year term at the current closing price.
- Granted 43,548 shares of restricted stock.
- Equity vests on a one-year anniversary or accelerates if not reelected/nominated for the 2025 annual meeting.
- Mr. Ward brings significant industry experience, having served as CEO of Cardiovascular Systems (acquired by Abbott) and held senior leadership roles at Medtronic.
InspireMD, Inc. filed an 8-K to announce the release of its financial and operating results for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure)
- Information provided in the press release (Exhibit 99.1) is furnished but not 'filed' for purposes of Section 18 liability.
InspireMD, Inc. entered into a 64-month lease agreement for approximately 10,782 square feet of office and shipping space in Miami, Florida. The company also issued a press release regarding the establishment of its global headquarters to support the commercialization of its CGuard Prime Carotid Stent System.
🚩 Red Flags
- Significant cash outlay ($500,000 security deposit) for a micro-cap company.
📋 Key Facts
- Entered into lease agreement with ROIB Waterford, LLC on October 9, 2024.
- Premises: ~10,782 sq. ft. in Suites 215 and 280 at 6303 Waterford District Drive, Miami, FL.
- Lease Term: 64 months from Commencement Date, with a five-year extension option.
- Security Deposit: $500,000 paid to the Landlord.
- Base Rent: $22,911.75 per month for the first year, increasing annually thereafter.
- Commencement is contingent upon completion of construction in Suite 280 and substantial completion in Suite 215.
InspireMD, Inc. announced that the FDA has approved its Investigational Device Exemption (IDE) application for the CGUARDIANS II pivotal study of the CGuard Prime 80cm Carotid Stent System.
📋 Key Facts
- FDA approved IDE Application for the CGUARDIANS II pivotal study on October 7, 2024.
- The study involves the CGuard Prime 80cm Carotid Stent System.
- The clinical application is specifically for use during transcarotid revascularization (TCAR) procedures.
InspireMD, Inc. has adopted a 2024 Inducement Plan to attract new employees without prior stockholder approval, utilizing Nasdaq Rule 5635(c)(4). The plan reserves 2,200,000 shares of common stock for restricted stock awards and RSUs.
🚩 Red Flags
- Potential dilution: The reservation of 2.2 million shares represents a new issuance of equity to attract talent.
📋 Key Facts
- The Board's compensation committee approved the '2024 Inducement Plan' on September 30, 2024.
- The plan was adopted without stockholder approval under Nasdaq Rule 5635(c)(4).
- A total of 2,200,000 shares of common stock have been reserved for issuance under this plan.
- Awards are limited to new employees or those returning after a bona fide period of non-employment.
- The plan includes restricted stock awards, nonqualified stock options (though the filing notes incentive stock options may not be issued), and RSUs.
InspireMD, Inc. announced the submission of a Premarket Approval (PMA) application to the FDA for its CGuard™ Prime Carotid Stent System. This filing is intended to seek regulatory approval for marketing the device in the United States.
📋 Key Facts
- On September 16, 2024, the Company submitted a PMA application to the FDA.
- The application is specifically for the CGuard™ Prime Carotid Stent System.
- The filing was made under Items 7.01 (Regulation FD Disclosure) and 8.01 (Other Events).
InspireMD, Inc. issued a press release announcing its financial and operating results for the three and six months ended June 30, 2024.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: August 6, 2024.
- The filing is a standard earnings release under Item 2.02.
InspireMD, Inc. announced the full exercise of its Series H warrants, resulting in $17.9 million in gross proceeds. The exercise converted warrants into common shares and pre-funded warrants to fund product development for CGuard Prime and SwitchGuard systems.
🚩 Red Flags
- Significant issuance of pre-funded warrants (over 12.5 million) which can lead to future dilution upon conversion.
- The exercise involves a large volume of shares/warrants relative to the common share count, typical of micro-cap financing structures.
📋 Key Facts
- Full exercise of 12.9 million Series H warrants completed on July 1, 2024.
- Gross proceeds: $17.9 million; Net proceeds (after fees): $16.9 million.
- Warrants converted into 292,996 common shares and 12,599,343 pre-funded warrants.
- Exercise price was $1.3827 per common share and $1.3826 per pre-funded warrant.
- Proceeds are earmarked for the CGuard Prime Transfemoral (CAS) delivery system and SwitchGuard trans carotid (TCAR) neuroprotection system.
InspireMD, Inc. has released an updated investor presentation via a Regulation FD disclosure. This filing is for informational purposes and does not contain material changes to the company's financial position or corporate structure.
📋 Key Facts
- The company made available an updated investor presentation on June 13, 2024.
- Information was provided pursuant to Item 7.01 (Regulation FD Disclosure).
- The presentation is furnished but not filed for purposes of Section 18 of the Exchange Act.
InspireMD, Inc. held its 2024 annual meeting of stockholders on June 10, 2024. The filing reports the results of shareholder votes regarding director elections, executive compensation, and auditor ratification.
📋 Key Facts
- Annual Meeting held on June 10, 2024.
- Quorum was met with 75% (17,716,035 shares) of the 23,401,435 outstanding shares represented.
- Paul Stuka and Gary Rubin were re-elected to the Board of Directors for three-year terms.
- Stockholders approved executive compensation via a nonbinding advisory vote.
- Stockholders voted to hold future advisory votes on executive compensation every 3 years.
- Kesselman & Kesselman (PwC member) was ratified as independent auditors for fiscal year 2024.
InspireMD, Inc. entered into a new $17 million Equity Distribution Agreement (ATM offering) with Piper Sandler & Co., replacing a previously terminated agreement with A.G.P./Alliance Global Partners.
🚩 Red Flags
- Potential for significant shareholder dilution through the $17M ATM offering.
- Frequent changes in sales agents/ATM structures (replacing A.G.P. with Piper Sandler) can sometimes indicate a need for continuous liquidity injection.
📋 Key Facts
- Entered into an Equity Distribution Agreement with Piper Sandler & Co. on May 31, 2024.
- The new offering allows for the sale of up to $17,000,000 of common stock via 'at the market' (ATM) methods.
- Piper Sandler will receive a commission of 3.0% on aggregate gross proceeds.
- Proceeds are intended for R&D, sales and marketing, working capital, and general corporate purposes.
- Terminated existing Sales Agreement with A.G.P./Alliance Global Partners effective May 31, 2024; no shares were sold under the prior agreement.
InspireMD, Inc. announced the presentation of positive one-year follow-up results from its C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the LINC 2024 conference.
📋 Key Facts
- The C-GUARDIANS Pivotal Trial enrolled 316 patients across 24 sites in the US and EU between July 2021 and June 2023.
- The primary endpoint was a composite of DSMI (death, stroke, or myocardial infarction) through 30 days post-procedure OR ipsilateral stroke from day 31 to day 365.
- The trial reported a primary endpoint event rate (DSMI rate) of 1.95%.
- Results were presented at the Leipzig Interventional Course (LINC) 2024.
InspireMD, Inc. filed an 8-K to furnish its quarterly financial and operating results for the first quarter ended March 31, 2024 via a press release.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Q1 ended March 31, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
InspireMD, Inc. entered into amendments to the employment agreements of its CEO (Marvin Slosman) and CFO/CAO (Craig Shore), specifically modifying severance terms triggered by a Change in Control.
🚩 Red Flags
- Significant increase in potential cash outflows/liabilities in the event of a merger or acquisition (Change in Control).
- The amendments specifically address 'termination without Cause' or non-renewal during a window surrounding a Change in Control, which can create misalignment between management and shareholders.
📋 Key Facts
- On April 1, 2024, the Company amended Marvin Slosman's (CEO) employment agreement regarding termination due to a Change in Control.
- Slosman Amendment includes severance pay equal to 24 months of base salary and two times his entire Performance Bonus upon specific change-in-control triggers.
- On April 1, 2024, the Company amended Craig Shore's (CFO/CAO) employment agreement regarding termination due to a Change in Control.
- Shore Amendment includes severance pay equal to 12 months of base salary and one times his Annual Bonus upon specific change-in-control triggers.
InspireMD, Inc. issued a press release regarding the acceptance of an abstract for its C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial one-year follow-up results to be presented at LINC 2024.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- Clinical trial: C-GUARDIANS U.S. Investigational Device Exemption (IDE).
- Event: One-year follow-up results accepted for presentation at LINC 2024.
- The information is furnished but not 'filed' under Section 18 of the Exchange Act.
InspireMD, Inc. filed an 8-K to announce its financial and operating results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Report date: March 6, 2024
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023
- The filing is a standard earnings release under Item 2.02 of Form 8-K.
InspireMD, Inc. announced that it has successfully received CE Mark recertification under the European Union’s new Medical Device Regulation (MDR) regulatory framework.
📋 Key Facts
- Company received CE Mark recertification under EU's MDR regulatory framework on January 31, 2024.
- The announcement was made via a press release attached as Exhibit 99.1.